BioSpace News Archive

Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended March 31, 2024, on Thursday, May 9, 2024.

Biogen Inc. announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders.

Theratechnologies Inc. announced that it will present long-term efficacy, safety and pharmacokinetic data on the use of its lead investigational peptide-drug conjugate candidate, TH1902, in patients with solid tumors.

Arbutus Biopharma Corporation today reports first quarter 2024 financial results and provides a corporate update.

Context Therapeutics Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody.

Context Therapeutics Inc. today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the first quarter ended March 31, 2024, and provided an update on the Company’s operations.

Guangzhou Bio-gene Technologies today announced that the first patient was treated with BG1805, an investigational autologous CAR-T cell therapy targeting CLL-1, a member of the C-type lectin-like receptor family.

Women’s health is often talked about in terms of major, life-altering events like pregnancy and menopause. A new study from Cold Spring Harbor Laboratory underscores the importance of considering everyday occurrences’ impact on women’s well-being.

Elevation Oncology, Inc. today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.